Combating the threat of anthrax: A quantitative structure - Activity relationship approach

Molecular Pharmaceutics

Volumn 5, Issue 5, 2008, Pages 745-759

  Verma, Rajeshwar P ^a   Hansch, Corwin ^a  

^a POMONA COLLEGE   (United States)

Author keywords

Anthrax; Bacillus anthracis; Hydrophobicity; Molar refractivity; Molar volume; QSAR

Indexed keywords

2,5 DIDEOXYSTREPTAMINE DERIVATIVE; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CLAVULANIC ACID; FRAMYCETIN; FRAMYCETIN DERIVATIVE; PENICILLIN DERIVATIVE; PHENYLFURAN 2 YLMETHYLENERHODANINE DERIVATIVE; TAZOBACTAM; UNCLASSIFIED DRUG;

ANTHRAX; ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS ANTHRACIS; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROPHOBICITY; IC 50; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY; VALIDATION PROCESS;

ANTHRAX; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BETA-LACTAMASES; COMPUTER SIMULATION; DRUG DESIGN; FURANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PENICILLINS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RHODANINE;

EID: 56049119877     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp8000149     Document Type: Article

References (84)

1. Puhar, A.; Montecucco, C. Where and how do anthrax toxins exit endosomes to intoxicate host cells? Trends Microbiol. 2007, 15, 477-482.
2. Jernigan, J. A.; Stephens, D. S.; Ashford, D. A.; Omenaca, C.; Topiel, M. S.; Galbraith, M.; Tapper, M.; Fisk, T. L.; Zaki, S.; Popovic, T.; Meyer, R. F.; Quinn, C. P.; Harper, S. A.; Fridkin, S. K.; Sejvar, J. J.; Shepard, C. W.; McConnell, M.; Guarner, J.; Shieh, W. J.; Malecki, J. M.; Gerberding, J. L.; Hughes, J. M.; Perkins, B. A. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerging Infect. Dis. 2001, 7 933-944.
3. Jernigan, D. B.; Raghunathan, P. L.; Bell, B. P.; Brechner, R.; Bresnitz, E. A.; Butler, J. C.; Cetron, M.; Cohen, M.; Doyle, T.; Fischer, M.; Greene, C.; Griffith, K. S.; Guarner, J.; Hadler, J. L.; Hayslett, J. A.; Meyer, R.; Petersen, L. R.; Phillips, M.; Pinner, R.; Popovic, T.; Quinn, C. P.; Reefhuis, J.; Reissman, D.; Rosenstein, N.; Schuchat, A.; Shieh, W.-J.; Siegal, L.; Swerdlow, D. L.; Tenover, F. C.; Traeger, M.; Ward, J. W.; Weisfuse, I.; Wiersma, S.; Yeskey, K.; Zaki, S.; Ashford, D. A.; Perkins, B. A.; Ostroff, S.; Hughes, J.; Fleming, D.; Koplan, J. P.; Gerberding, J. L. Investigation of bioterrorism-related anthrax, United States, 2001: Epidemiologic findings. Emerging Infect. Dis. 2002, 8, 1019-1028.
4. Griffith, K. S.; Mead, P.; Armstrong, G. L.; Painter, J.; Kelley, K. A.; Hoffmaster, A. R.; Mayo, D.; Barden, D.; Ridzon, R.; Parashar, U.; Teshale, E. H.; Williams, J.; Noviello, S.; Perz, J. F.; Mast, E. E.; Swerdlow, D. L.; Hadler, J. L. Bioterrorism-related inhalational anthrax in an elderly woman, Connecticut, 2001. Emerging Infect. Dis. 2003, 9, 681-688.
5. Matsumoto, G. Bioterrorism Anthrax powder: State of the art. Science 2003, 302, 1492-1497.
6. Atlas, R. M. The medical threat of biological weapons. Crit. Rev. Microbiol. 1998, 24, 157-168.
7. Collier, R. J.; Young, J. A. T. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 2003, 19, 45-70.
8. Guidi-Rontani, C.; Mock, M. Macrophage interactions. Curr. Top. Microbiol. Immunol. 2002, 271, 115-141.
9. WHO. Health aspect of chemical and biological weapons; WHO: Geneva, Switzerland, 1970.
10. Spencer, R. C. Bacillus anthracis. J. Clin. Pathol. 2003, 56, 182-187.
11. Bouzianas, D. G. Potential biological targets of bacillus anthracis in anti-infective approaches against the threat of bioterrorism. Expert Rev. Anti-Infect. Ther. 2007, 5, 665-684.
12. Stubbs II, M. T. Anthrax X-rayed: New opportunities for biodefence. Trends Pharmacol Sci. 2002, 23, 539-541.
13. Cavallo, J.-D.; Ramisse, F.; Girardet, M.; Vaissaire, J.; Mock, M.; Hernandez, E. Antibiotic susceptibilities of 96 isolates of bacillus anthracis isolated in France between 1994 and 2000. Antimicrob. Agents Chemother. 2002, 46, 2307-2309.
14. Brook, I.; Elliott, T. B.; Pryor, H. I. 2nd.; Sautter, T. E.; Gnade, B. T.; Thakar, J. H.; Knudson, G. B. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int. J. Antimicrob. Agents 2001, 18, 559-562.
15. Petrosino, J.; Cantu, C., III; Palzkill, T. Beta-Lactamases: Protein evolution in real time. Trends Microbiol. 1998, 6, 323-327.
16. Theuretzbacher, U. Beta lactamases and beta - lactamase inhibitors. Chemother. J. 1998, 7, 136-142.
17. Majiduddin, F. K.; Materon, I. C.; Palzkill, T. G. Molecular analysis of beta-lactamase structure and function. Int. J. Med. Microbiol. 2002, 292, 127-137.
18. Chen, Y.; Succi, J.; Tenover, F. C.; Koehler, T. M. β-lactamase genes of the penicillin-susceptible bacillus anthracis sterne strain. J. Bacteriol. 2003, 185, 823-830.
19. Beharry, Z.; Chen, H.; Gadhachanda, V. R.; Buynak, J. D.; Palzkill, T. Evaluation of penicillin-based inhibitors of the class A and B beta-lactamases from bacillus anthracis. Biochem. Biophys. Res. Commun. 2004, 313, 541-545.
20. Kubler-Kielb, J.; Liu, T.-Y.; Mocca, C.; Majadly, F.; Robbins, J. B.; Schneerson, R. Additional conjugation methods and immunogenicity of Bacillus anthracis poly-γ-D-glutamic acid-protein conjugates. Infect. Immun. 2006, 74, 4744-4749.
21. Candela, T.; Fouet, A. Poly-gamma-glutamate in bacteria. Mol. Microbiol. 2006, 60, 1091-1098.
22. Duesbery, N. S.; Webb, C. P.; Leppla, S. H.; Gordon, V. M.; Klimpel, K. R.; Copeland, T. D.; Ahn, N. G.; Marianne, M. K.; Fukasawa, K.; Paull, K. D.; Vande Woude, G. F. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998, 280, 734-737.
23. Young, J. A. T.; Collier, R. J. Anthrax toxin: Receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 2007, 76, 243-265.
24. Pitt, M. L. M.; Little, S. F.; Ivins, B. E.; Fellows, P.; Barth, J.; Hewetson, J.; Gibbs, P.; Dertzbaugh, M.; Friedlander, A. M. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 2001, 19, 4768-4773.
25. Xie, H.; Gursel, I.; Ivins, B. E.; Singh, M.; O'Hagan, D. T.; Ulmer, J. B.; Klinman, D. M. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun. 2005, 73, 828-833.
26. McConnell, M. J.; Hanna, P. C.; Imperiale, M. J. Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol. Ther. 2007, 15, 203-210.
27. Pezard, C.; Berche, P.; Mock, M. Contribution of individual toxin components to virulence of bacillus anthracis. Infect. Immun. 1991, 59, 3472-3477.
28. Montecucco, C.; Tonello, F.; Zanotti, G. Stop the Killer: How to inhibit the anthrax lethal factor metalloprotease. Trends Biochem. Sci. 2004, 29, 282-285.
29. Gaddis, B. D.; Avramova, L. V.; Chmielewski, J. Inhibitors of anthrax lethal factor. Bioorg. Med. Chem. Lett. 2007, 17, 4575-4578.
30. Barrow, E. W.; Bourne, P. C.; Barrow, W. W. Functional cloning of bacillus anthracis dihydrofolate reductase and confirmation of natural resistance to trimethoprim. Antimicrob. Agents Chemother. 2004, 48, 4643-4649.
31. Bennett, B. C.; Xu, H.; Simmerman, R. F.; Lee, R. E.; Dealwis, C. G. Crystal structure of the anthrax drug target, bacillus anthracis dihydrofolate reductase. J. Med. Chem. 2007, 50, 4374-4381.
32. Barrow, E. W.; Dreier, J.; Reinelt, S.; Bourne, P. C.; Barrow, W. W. In vitro efficacy of new antifolates against trimethoprim-resistant bacillus anthracis. Antimicrob. Agents Chemother. 2007, 51, 4447-4452.
33. Hansch, C.; Maloney, P. P.; Fujita, T.; Muir, R. M. Correlation of biological activity of phenoxyacetic acids with Hammett substituent constants and partition coefficients. Nature 1962, 194, 178-180.
34. Hansch, C.; Leo, A. In Exploring QSAR: Fundamentals and Applications in Chemistry and Biology; American Chemical Society: Washington, DC, 1995.
35. Selassie, C. D.; Garg, R.; Kapur, S.; Kurup, A.; Verma, R. P.; Mekapati, S. B.; Hansch, C. Comparative QSAR and the radical toxicity of various functional groups. Chem. Rev. 2002,102, 2585-2605.
36. Verma, R. P.; Kurup, A.; Mekapati, S. B.; Hansch, C. Chemical-biological interactions in human. Bioorg. Med. Chem. 2005, 13, 933-948.
37. Hansch, C.; Leo, A.; Mekapati, S. B.; Kurup, A. QSAR and ADME. Bioorg. Med. Chem. 2004, 12, 3391-3400.
38. Verma, R. P.; Hansch, C.; Selassie, C. D. Comparative QSAR studies on PAMPA/modified PAMPA for high throughput profiling of drug absorption potential with respect to Caco-2 cells and human intestinal absorption. J. Comput. Aided. Mol. Des. 2007, 21, 3-22.
39. Selassie, C. D.; Mekapati, S. B.; Verma, R. P. QSAR: Then and now. Curr. Top. Med. Chem. 2002, 2, 1357-1379.
40. C-QSAR Program, BioByte Corp., 201W. 4th St., Suite 204, Claremont, CA 91711, USA, www.biobyte.com.
41. Hansch, C.; Hoekman, D.; Leo, A.; Weininger, D.; Selassie, C. D. Chem-Bioinformatics: Comparative QSAR at the interface between chemistry and biology. Chem. Rev. 2002, 102, 783-812.
42. Verma, R. P.; Hansch, C. Development of QSAR models using C-QSAR program: A regression program that has dual databases of over 21,000 QSAR models. Nat. Protoc. (DOI: 10.1038/nprot.2007.125). Freely available at http://www.natureprotocols.com/2007/03/05/ development_of_qsar_models_usi_1.php.
43. Abraham, M. H.; McGowan, J. C. The use of characteristic volumes to measure cavity terms in reversed phase liquid chromatography. Chromatographia 1987, 23, 243-246.
44. Cramer, R. D., III; Bunce, J. D.; Patterson, D. E.; Frank, I. E. Cross validation, Bootstrapping and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
45. Pogliani, L. Modeling with special descriptors derived from a medium-sized set of connectivity indices. J. Phys. Chem. 1996, 100, 18065-18077.
46. Pogliani, L. From molecular connectivity indices to semiempirical connectivity terms: Recent trends in graph theoretical descriptors. Chem. Rev. 2000, 100, 3827-3858.
47. Selassie, C. D.; Kapur, S.; Verma, R. P.; Rosario, M. Cellular apoptosis and cytotoxicity of phenolic compounds: A quantitative structure-activity relationship study. J. Med. Chem. 2005, 48, 7234-7242.
48. Verma, R. P.; Hansch, C. Cytotoxicity of organic compounds against ovarian cancer cells: A quantitative structure-activity relationship study. Mol. Pharmaceutics 2006, 3, 441-450.
49. Verma, R. P.; Hansch, C. Matrix metalloproteinases (MMPs): Chemical-biological functions and QSARs. Bioorg. Med. Chem. 2007, 15, 2223-2268.
50. Verma, R. P.; Hansch, C. Understanding human rhinovirus infections in terms of QSAR. Virology 2007, 359, 152-161.
51. Hansch, C.; Verma, R. P. 20-(S)-Camptothecin analogues as DNA topoisomerase I inhibitors: A QSAR study. ChemMedChem 2007, 2, 1807-1813.
52. Verma, R. P.; Hansch, C. Investigation of DNA-binding properties of organic molecules using quantitative structure-activity relationship (QSAR) models. J. Pharm. Sci. 2008, 97, 88-110.
53. Verma, R. P.; Hansch, C. An approach toward the problem of outliers in QSAR. Bioorg. Med. Chem. 2005, 13, 4597-4621.
54. Polanski, J.; Bak, A.; Gieleciak, R.; Magdziarz, T. Modeling Robust QSAR. J. Chem. Inf. Model. 2006, 46, 2310-2318.
55. Ekins, S.; Mestres, J.; Testa, B. In silico pharmacology for drug discovery: Methods for virtual ligand screening and profiling. Br. J. Pharmacol. 2007, 152, 9-20.
56. Bennett, C. A.; Franklin, N. L. In Statistical Analysis in Chemistry and the Chemical Industry; John Wiley & Sons: New York, 1967; pp 708-709. (5th printing).
57. Forino, M.; Johnson, S.; Wong, T. Y.; Rozanov, D. V.; Savinov, A. Y.; Li, W.; Fattorusso, R.; Becattini, B.; Orry, A. J.; Jung, D.; Abagyan, R. A.; Smith, J. W.; Alibek, K.; Liddington, R. C.; Strongin, A. Y.; Pellecchia, M. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 9499-9504.
58. Verma, R. P. Understanding topoisomerase I and II in terms of QSAR. Bioorg. Med. Chem. 2005, 13, 1059-1067.
59. Mekapati, S. B.; Kurup, A.; Verma, R. P.; Hansch, C. The role of hydrophobic properties of chemicals in promoting allosteric reactions. Bioorg. Med. Chem. 2005, 13, 3737-3762.
60. Verma, R. P. An approach towards the quantitative structure-activity relationships for sulfamate-based estrone sulfatase inhibitors. Lett. Drug Des. Discovery 2005, 2, 205-218.
61. Hansch, C.; Verma, R. P. Understanding tubulin/microtubule-taxane interactions: A quantitative structure-activity relationship study. Mol. Pharmaceutics 2008, 5, 151-161.
62. Monod, J.; Changeux, J.-P.; Jacob, F. Allosteric proteins and cellular control systems. J. Mol. Biol. 1963, 6, 306-329.
63. Koshland, D. E., Jr. In The Enzymes; Boyer, P., Ed.; Academic Press: New York, 1970; Vol. 1, p 341.
64. Changeux, J.-P.; Edelstein, S. J. Allosteric receptors after 30 years. Neuron 1998, 21, 959-980.
65. Kovbasyuk, L.; Krämer, R. Allosteric supramolecular receptors and catalysts. Chem. Rev. 2004, 104, 3161-3187.
66. Johnson, S. L.; Jung, D.; Forino, F.; Chen, Y.; Satterthwait, A.; Rozanov, D. V.; Strongin, A. Y.; Pellecchia, M. Anthrax lethal factor protease inhibitors: Synthesis, SAR, and structure-based 3D QSAR studies. J. Med. Chem. 2006, 49, 27-30.
67. Selassie, C. D.; Garg, R.; Mekapati, S. Mechanism-based QSAR approach to the study of the toxicity of endocrine active substances. Pure Appl. Chem. 2003, 75, 2363-2373.
68. Roncaglioni, A.; Benfenati, E. In silico-aided prediction of biological properties of chemicals: Oestrogen receptor-mediated effects. Chem. Soc. Rev. 2008, 37, 441-450.
69. Hughes, R. A.; Harris, T.; Altmann, E.; McAllister, D.; Vlahos, R.; Robertson, A.; Cushman, M.; Wang, Z.; Stewart, A. G. 2-Methoxyestradiol and analogs as novel antiproliferative agents: Analysis of three-dimensional quantitative structure-activity relationships for DNA synthesis inhibition and estrogen receptor binding. Mol. Pharmacol. 2002, 61, 1053-1069.
70. Jacobsen, F. E.; Lewis, J. A.; Cohen, S. M. A new role for old ligands: discerning chelators for zinc metalloproteinases. J. Am. Chem. Soc. 2006, 128, 3156-3157.
71. Johnson, S. L.; Chen, L.-H.; Pellecchia, M. A high-throughput screening approach to anthrax lethal factor inhibition. Bioorg. Chem. 2007, 35, 306-312.
72. Fridman, M.; Belakhov, V.; Lee, L. V.; Liang, F.-S.; Wong, C.-H.; Baasov, T. Dual effect of synthetic aminoglycosides: Anti-bacterial activity against Bacillus anthracis and inhibition of anthrax lethal factor. Angew. Chem., Int. Ed. 2005, 44, 447-452.
73. Turk, B. E.; Wong, T. Y.; Schwarzenbacher, R.; Jarrell, E. T.; Leppla, S. H.; Collier, R. J.; Liddington, R. C.; Cantley, L. C. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol. 2004, 11, 60-66.
74. Panchal, R. G.; Hermone, A. R.; Nguyen, T. L.; Wong, T. Y.; Schwarzenbacher, R.; Schmidt, J.; Lane, D.; McGrath, C.; Turk, B. E.; Burnett, J.; Aman, M. J.; Little, S.; Sausville, E. A.; Zaharevitz, D. W.; Cantley, L. C.; Liddington, R. C.; Gussio, R.; Bavari, S. Identification of small molecule inhibitors of anthrax lethal factor. Nat. Struct. Mol. Biol. 2004, 11, 67-72.
75. Jiao, G.-S.; Cregar, L.; Goldman, M. E.; Millis, S. Z.; Tang, C. Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 1527-1531.
76. Luedtke, N. W.; Carmichael, P.; Tor, Y. Cellular uptake of aminoglycosides, guanidinoglycosides, and poly-arginine. J. Am. Chem. Soc. 2003, 125, 12374-12375.
77. Ding, Y.; Hofstadler, S. A.; Swayze, E. E.; Griffey, R. H. An efficient synthesis of mimetics of neamine for RNA recognition. Org. Lett. 2001, 3, 1621-1623.
78. Vourloumis, D.; Takahashi, M.; Winters, G. C.; Simonsen, K. B.; Ayida, B. K.; Barluenga, S.; Qamar, S.; Shandrick, S.; Zhao, Q.; Hermann, T. Novel 2,5-dideoxystreptamine derivatives targeting the ribosomal decoding site RNA. Bioorg. Med. Chem. Lett. 2002, 12, 3367-3372.
79. Pannifer, A. D.; Wong, T. Y.; Schwarzenbacher, R.; Renatus, M.; Petosa, C.; Blenkowska, J.; Lacy, D. B.; Collier, R. J.; Park, S.; Leppla, S. H.; Hanna, P.; Liddington, R. C. Crystal structure of the anthrax lethal factor. Nature 2001, 414, 229-233.
80. 2! J. Mol. Graphics Modell. 2002, 20, 269-276.
81. Tropsha, A.; Gramatica, P.; Gombar, V. K. The importance of being earnest: Validation is the absolute essenfial for successful application and interpretation of QSPR models. QSAR Comb. Sci. 2003, 22, 69-77.
82. Wold, S.; Eriksson, L. In Chemometrics Methods in Molecular Design: Statistical Validation of QSAR Results; van de Waterbeemd, H., Ed.; VCH: Weinheim, Germany, 1995; pp 309-318.
83. Melzig, M. F.; Tran, G. D.; Henke, K.; Selassie, C. D.; Verma, R. P. Inhibition of neutrophil elastase and thrombin activity by caffeic acid esters. Pharmazie 2005, 60, 869-873.
84. Zhang, S.; Golbraikh, A.; Oloff, S.; Kohn, H.; Tropsha, A. A novel automated lazy learning QSAR (ALL-QSAR) approach: Method development, applications, and virtual screening of chemical databases using validated ALL-QSAR models. J. Chem. Inf. Model. 2006, 46, 1984-1995.